End Of The 'March-In' Pricing Petitions?
Executive Summary
KEI vows to continue battle over Bayh-Doyle restrictions after US Commerce Department suggests it may issue regulations to exclude pricing as a basis for requiring companies to license their patents.
You may also be interested in...
HIV PrEP Patent Dispute Escalates As HHS Files Suit Against Gilead
Trump administration wants the HIV drug maker to license HHS patents related to pre-exposure prophylaxis. Lawsuit follows Gilead’s request in August for the USPTO’s PTAB to conduct an inter partes review of the four-year-old patents.
HIV PrEP Patent Dispute Escalates As HHS Files Suit Against Gilead
Trump administration wants the HIV drug maker to license HHS patents related to pre-exposure prophylaxis. Lawsuit follows Gilead’s request in August for the USPTO’s PTAB to conduct an inter partes review of the four-year-old patents.
Building A Wall? The Plan To End “March In” Threat To US Drug Patents
Calls to exercise “march in” rights on federal patents licensed to pharmaceutical companies are a recurring theme in the US drug pricing debate. Now the Department of Commerce is proposing to make those threats even emptier than they already are.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: